Logo

Biomarker Strategies: Greg Bertenshaw

Jun 05, 2020

Biomarker Strategies has promoted Greg Bertenshaw to the position of chief operating and science officer. Bertenshaw was formerly vice president of R&D and director of R&D for the company, which he joined in 2011 as a senior scientist. Bertenshaw has also previously served as director of new technology for Correlogic Systems, and as a scientist and director of science for Clearant. He holds a PhD in biochemistry and molecular biology from Penn State University College of Medicine.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.